Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine symbols : Ino save search
Global Vaccines Market Research Report 2022-2027: A $200+ Billion Industry - Forecasts, Company Market Share and Expert Market Estimates for Vaccine Categories
Published: 2023-02-08 (Crawled : 16:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.09%
H: 1.26%
C: 0.99%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.06%
H: 0.77%
C: 0.19%
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.78%
H: 0.79%
C: -5.29%
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: -0.07%
H: 4.9%
C: 2.27%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: -4.13%
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -1.61%
H: 2.73%
C: -8.47%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.35%
H: 1.53%
C: 0.68%
research global report vaccine market
INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800
Published: 2022-10-27 (Crawled : 21:00) - prnewswire.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -4.37%
H: 12.69%
C: 12.18%
covid-19 ino-4800 vaccine update
Human Papillomavirus Vaccine (HPV) Market to Reach $10.8 Bn, Globally, by 2031 at 12.4% CAGR: Allied Market Research
Published: 2022-07-21 (Crawled : 13:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 6.64%
H: 0.0%
C: -4.08%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.38%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: -3.5%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.09%
H: 1.9%
C: 1.89%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.18%
H: 0.0%
C: 0.0%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 1.3%
H: 0.38%
C: -0.38%
XBIO | $4.14 7.32% 770
|
Health Technology
|
| O: 0.41%
H: 7.44%
C: -2.71%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -3.38%
H: 0.0%
C: 0.0%
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 0.0%
H: 1.35%
C: -5.83%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.75%
H: 2.31%
C: 2.15%
research vaccine market
INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201
Published: 2021-11-16 (Crawled : 13:30) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: 0.0%
vaccine trial
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.
Published: 2021-11-09 (Crawled : 13:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 4.79%
H: 7.71%
C: 0.71%
covid fda vaccine phase 3 ino-4800
INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India
Published: 2021-11-03 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.35%
H: 0.81%
C: 0.67%
covid india vaccine phase 3 trial ino-4800
INOVIO Completes Enrollment of Phase 1B Clinical Trial for its DNA Vaccine Candidate Against Lassa Fever, INO-4500, in West Africa
Published: 2021-10-26 (Crawled : 13:00) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
phase 1 phase 1b vaccine trial ino-4800 enroll phase 2b africa
INOVIO Announces Online Preprint Publication of Homologous Boosting Data for its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-10-12 (Crawled : 13:00) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.06%
H: 0.58%
C: -0.29%
covid vaccine ino-4800
INOVIO Expands INNOVATE Phase 3 for INO-4800, its DNA Vaccine Candidate for COVID-19, to include Colombia following Regulatory Authorization
Published: 2021-10-11 (Crawled : 12:00) - prnewswire.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -1.21%
H: 5.95%
C: 3.82%
covid vaccine phase 3 authorized ino-4800
INOVIO Receives Regulatory Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800, in Mexico
Published: 2021-09-22 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 0.25%
H: 0.76%
C: -1.14%
covid vaccine phase 3 trial authorized ino-4800
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-08-26 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 4.86%
H: 8.36%
C: -1.69%
covid vaccine phase 3 trial authorized ino-4800
INOVIO and Advaccine Receive Regulatory Allowance for Two Heterologous Prime-Boost Clinical Trials in China Using INO-4800, INOVIO’s COVID-19 DNA Vaccine Candidate
Published: 2021-08-09 (Crawled : 12:00) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -1.16%
H: 8.32%
C: 4.77%
covid clinical trials china vaccine trial ino-4800 primec
INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease
Published: 2021-08-04 (Crawled : 13:00) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -6.97%
H: 13.21%
C: 9.36%
disease phase 2 respiratory vaccine trial syndros
INOVIO Expands Partnership with Advaccine to Conduct Global Phase 3 Efficacy Trial of COVID-19 DNA Vaccine Candidate, INO-4800
Published: 2021-06-08 (Crawled : 12:15) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.49%
H: 0.46%
C: -0.69%
covid partnership vaccine phase 3 trial ino-4800
Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program
Published: 2021-06-03 (Crawled : 13:15) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -0.75%
H: 4.43%
C: -0.13%
cancer vaccine therapeutics program
INOVIO’s Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies
Published: 2021-05-12 (Crawled : 12:00) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 1.39%
H: 0.3%
C: -4.26%
covid vaccine ino-4800 preclinical pre-clinical
INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine
Published: 2021-05-10 (Crawled : 12:00) - prnewswire.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.04%
H: 3.0%
C: -4.58%
covid phase 2 positive vaccine trial ino-4800
INOVIO’s COVID-19 Vaccine Candidate, INO-4800, Provides Broad Cross-reactive Immune Responses In Humans Against Variants of Concern
Published: 2021-04-15 (Crawled : 12:00) - inovio.com
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 11.09%
H: 5.6%
C: -8.25%
covid vaccine ino-4800 response
INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa
Published: 2021-02-23 (Crawled : 18:00) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: -6.06%
H: 0.33%
C: -3.47%
phase 1 vaccine trial phase 1b ino-4800 phase 2b africa
INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
Published: 2021-01-04 (Crawled : 16:00) - biospace.com/
INO 4 d | $9.68 -5.1% -5.37% 350K
|
Health Technology
|
| O: 2.26%
H: 8.51%
C: 7.51%
covid china vaccine partnership commercialization ino-4800
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.